Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Non-cash Items (2021 - 2025)

Aligos Therapeutics' Non-cash Items history spans 5 years, with the latest figure at $55234.0 for Q4 2025.

  • For Q4 2025, Non-cash Items fell 99.48% year-over-year to $55234.0; the TTM value through Dec 2025 reached $55234.0, down 99.48%, while the annual FY2025 figure was $55234.0, 99.48% down from the prior year.
  • Non-cash Items reached $55234.0 in Q4 2025 per ALGS's latest filing, down from $1.2 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $47.1 million in Q2 2021 to a low of $55234.0 in Q4 2025.
  • Average Non-cash Items over 5 years is $5.6 million, with a median of $3.0 million recorded in 2022.
  • Peak YoY movement for Non-cash Items: skyrocketed 3775.37% in 2023, then crashed 99.48% in 2025.
  • A 5-year view of Non-cash Items shows it stood at $16.8 million in 2021, then crashed by 77.75% to $3.7 million in 2022, then skyrocketed by 62.19% to $6.0 million in 2023, then skyrocketed by 75.4% to $10.6 million in 2024, then plummeted by 99.48% to $55234.0 in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Non-cash Items are $55234.0 (Q4 2025), $1.2 million (Q3 2025), and $307792.0 (Q2 2025).